Herzog, Chiara http://orcid.org/0000-0002-1572-498X
Jones, Allison
Evans, Iona http://orcid.org/0000-0002-0225-3154
Zikan, Michal
Cibula, David
Harbeck, Nadia http://orcid.org/0000-0002-9744-7372
Colombo, Nicoletta
Rådestad, Angelique Flöter
Gemzell-Danielsson, Kristina http://orcid.org/0000-0001-6516-1444
Pashayan, Nora http://orcid.org/0000-0003-0843-2468
Widschwendter, Martin http://orcid.org/0000-0002-7778-8380
Article History
Received: 27 March 2023
Accepted: 13 September 2023
First Online: 27 September 2023
Competing interests
: C.H. and M.W. are shareholders of Sola Diagnostics GmbH, which holds an exclusive licence to the intellectual property that protects the commercialisation of the WID™-qtBC test. N.H. receives Honoraria for consulting and/or lectures (which are outside the remit of this work) from Astra Zeneca, Daiichi-Sankyo, Gilead, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sanofi, Sandoz, and Seagen. All other authors declare no competing interests.
: For the FORECEE programme, ethical approval was provided from the UK Health Research Authority (REC 14/LO/1633) and other contributing centres. For the breast tissue samples ethical approval was obtained from the NRES Committee East of England (reference number 15/EE/0192). The Mifepristone trial was approved by the regional ethical review board at Karolinska Institutet permit 2009/144-31/4 and the regional ethical review board at Karolinska Institutet permit 2012/729 31/1.